LaaGuarder: first European clinical use announced by EUKON
In January 2026, EUKON announced the first clinical use in…
Supraflex Cruz evidence presented at TCT 2025
In November 2025, EUKON shared an update from Sahajanand Medical Technologies (SMT) on clinical evidence presented at TCT 2025 for the Supraflex Cruz drug-eluting stent.
The update brought together four programmes: TUXEDO II, Multivessel TALENT, the Cruz Senior Study and the SFlex Netherlands Registry. These studies address different clinical settings and patient populations, contributing to discussion of contemporary coronary intervention.
Healthcare professionals can consult the original study reports and conference presentations to review their individual designs, endpoints and limitations. Findings from separate studies should be assessed in their respective clinical contexts.
Read EUKON’s update of 6 November 2025.
Read SMT’s overview of the four TCT 2025 programmes, or contact EUKON for product information.
Latest News:
Supraflex Cruz NEVO now available to Italian cath labs
EUKON announced the availability of Supraflex Cruz NEVO to Italian…
AIR-STEMI: new evidence for physiology-guided revascularisation
The AIR-STEMI trial was presented by Associate Professor Simone Biscaglia…